Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade

Nature Reviews Urology, Published online: 11 November 2022; doi:10.1038/s41585-022-00666-2Adjuvant therapies in renal cell carcinoma (RCC) disrupt multiple steps of the metastatic cascade. Results from clinical trials to assess adjuvant treatment with immunotherapeutic agents in patients with resected clear cell RCC were promising, but the utility of tyrosine kinase inhibitors in this setting was not clearly shown. In this Perspective, the authors provide an overview of completed and ongoing clinical trials for adjuvant treatment of RCC, highlighting future directions and challenges in the field.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research